Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are dihydrofuropyridine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).

Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are dihydrofuropyridine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).

Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are dihydrofuropyridine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).

Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are dihydrofuropyridine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).

Abstract: A method for determining prospective peering partners for an internet service provider, includes gathering internet service provider's routing and traffic information; gathering additional routing information from sources other than the internet service provider; identifying uncovered target autonomous systems based on the internet service provider's routing and traffic information, the uncovered target autonomous systems being autonomous systems with non-null traffic and that are reachable by the internet service provider via a transit relationship; identifying paths from the internet service provider to the uncovered target autonomous systems based on the additional routing information; identifying intermediate autonomous systems along the identified paths; and determining at least a prospective peering partner for the internet service provider based on the identified intermediate autonomous systems.

Abstract: A method for determining prospective peering partners for an internet service provider, includes gathering internet service provider's routing and traffic information; gathering additional routing information from sources other than the internet service provider; identifying uncovered target autonomous systems based on the internet service provider's routing and traffic information, the uncovered target autonomous systems being autonomous systems with non-null traffic and that are reachable by the internet service provider via a transit relationship; identifying paths from the internet service provider to the uncovered target autonomous systems based on the additional routing information; identifying intermediate autonomous systems along the identified paths; and determining at least a prospective peering partner for the internet service provider based on the identified intermediate autonomous systems.